Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance

Dianthus Therapeutics, Inc. /DE/

2026-Q1 EPS reported -$0.85

Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.
Cash $1.2B at March 31, including $719M gross from March public offering; runway into 2030.
Claseprubart: Early GO in CAPTIVATE CIDP trial; Phase 3 gMG trial mid-2026 with top-line 2H'28.
DNTH212: Priority indications SjD, SLE, DM; Phase 1 healthy volunteer data expected 2H'26.
Orphan Drug Designation for claseprubart in MG; FDA agreed to remove ANA screening and DIL reclassification.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ reported financial results for the first quarter ending March 31, 2026.

Period: the first quarter ending March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001690585-26-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.